These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 27060634)

  • 41. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 42. [Recent studies on tumor immunity and prospects for therapy of neoplasms].
    Aoki Y; Tanaka K
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Aug; 47(8):863-71. PubMed ID: 7594896
    [No Abstract]   [Full Text] [Related]  

  • 43. Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.
    Demaria O; Gauthier L; Debroas G; Vivier E
    Eur J Immunol; 2021 Aug; 51(8):1934-1942. PubMed ID: 34145579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunocytokines: a new approach to immunotherapy of melanoma.
    Reisfeld RA; Becker JC; Gillies SD
    Melanoma Res; 1997 Aug; 7 Suppl 2():S99-106. PubMed ID: 9578424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 47. Breakthrough of the year 2013. Cancer immunotherapy.
    Couzin-Frankel J
    Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
    [No Abstract]   [Full Text] [Related]  

  • 48. Emerging immunologic approaches to treatment of neoplastic diseases.
    Olsson L; Mathé G
    Recent Results Cancer Res; 1982; 80():334-7. PubMed ID: 6977172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-cell-independent antitumor effects of CD40 ligation.
    Rakhmilevich AL; Alderson KL; Sondel PM
    Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytokine/Antibody Fusion Protein Design and Evaluation.
    Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
    Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on the current revolution in cancer immunotherapy.
    Renrick AN; Dunbar ZT; Shanker A
    Immunotherapy; 2019 Jan; 11(1):15-20. PubMed ID: 30702010
    [No Abstract]   [Full Text] [Related]  

  • 52. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.
    Tzeng A; Kwan BH; Opel CF; Navaratna T; Wittrup KD
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3320-5. PubMed ID: 25733854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunology. Considering therapeutic antibodies.
    Vitetta ES; Ghetie VF
    Science; 2006 Jul; 313(5785):308-9. PubMed ID: 16857927
    [No Abstract]   [Full Text] [Related]  

  • 55. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunocytokines: amplification of anti-cancer immunity.
    Davis CB; Gillies SD
    Cancer Immunol Immunother; 2003 May; 52(5):297-308. PubMed ID: 12700945
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. STING signaling: a key to therapeutic tumor immunity.
    Foote JB; Emens LA
    Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
    [No Abstract]   [Full Text] [Related]  

  • 60. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
    Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.